Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Cocrystal Pharma, Inc. logo — The company's focus is on developing antiviral therapeutics...

Cocrystal Pharma, Inc.

The company's focus is on developing antiviral therapeutics for the treatment of serious and/or chronic viral diseases

Founded 2004 United States Bothell, United States 16 employees IPO Total: $89.88M Pharmaceutical

General Information

Company Name Cocrystal Pharma, Inc.
Founded Year 2004
Location United States Bothell, United States
Employees 16
Industries Pharmaceutical
Funding Stage IPO
Business Model B2B
Revenue Model Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Cocrystal Pharma, Inc.. To contact Cocrystal Pharma, Inc., visit cocrystalpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cocrystal Pharma, Inc. compare?

A PDF of Cocrystal Pharma, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cocrystal Pharma, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical-stage biotechnology company that is pioneering the development of novel antiviral therapeutics targeting the replication machinery of critical viruses like COVID-19, influenza, and noroviruses. Founded in 2004, the company leverages unique structure-based technologies alongside expertise informed by Nobel Prize-winning science to create first- and best-in-class drugs aimed at treating serious and chronic viral diseases.

Currently, Cocrystal Pharma is enrolling subjects in a Phase 1 trial for an antiviral candidate targeting pandemic and seasonal influenza A. The firm also has plans to commence clinical trials for COVID-19 in 2022, including both orally administered and inhalation/pulmonary delivered candidates.

The pharmaceutical sector witnessed National Institute of Health stepping in as the latest investor, contributing a $500,000 post-IPO equity investment as of October 1, 2025. The prominence of their investment accentuates faith in Cocrystal Pharma's disruptive potential within the antiviral therapeutic landscape.

Business keywords: antiviral therapeutics, clinical-stage biotechnology, COVID-19 therapeutics, influenza viruses, noroviruses, structure-based drug design, replication machinery targeting, Nobel Prize expertise, Phase 1 clinical trial, pandemic influenza, seasonal influenza, orally administered antivirals, inhalation/pulmonary delivery, small molecule therapeutics, chronic viral diseases

Services & Products

Drug Development
Antiviral Research
Clinical Trials
Nobel Prize-winning Expertise

Target Customers

Healthcare Providers Pharmaceutical Companies Biotechnology Researchers Patients with Viral Diseases

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $500.00K 1
National Institute of Health
National Institute of Health
01 Oct 2025
Post-IPO Equity $40.00M -
01 May 2021
Post-IPO Equity $17.20M -
01 Aug 2020
Post-IPO Equity $20.00M -
01 Mar 2020
Post-IPO Equity $4.18M -
01 Mar 2019
Post-IPO Equity $3.00M -
01 May 2017
Early VC $5.00M -
01 Mar 2016
IPO Undisclosed -
01 May 2011
Spinout Undisclosed 2
University Ventures
University Ventures, Stanford University
01 Jan 2004

Cocrystal Pharma, Inc. Alternatives & Competitors

View All Alternatives
Cocrystal Pharma, Inc. vs
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH Germany

Clinical stage biopharmaceutical company spearheading antiviral drug innovation

Debt Financing
14 employees
Biopharma, Biotechnology
Cocrystal Pharma, Inc. vs
Tvardi Therapeutics
Tvardi Therapeutics United States

Breakthrough Medicines for Cancer, Chronic Inflammation & Fibrosis

Series B
18 employees
Biotechnology, Health Care
Cocrystal Pharma, Inc. vs
Redx Pharma
Redx Pharma United Kingdom

Biotech company focusing on the discovery and development of novel targeted medicines to treat cance...

Post-IPO Equity
39 employees
Biotechnology, Health Care
View all alternatives

FAQ About Cocrystal Pharma, Inc.

The company's focus is on developing antiviral therapeutics for the treatment of serious and/or chronic viral diseases
Cocrystal Pharma, Inc. was founded in 2004.
Cocrystal Pharma, Inc. is headquartered in Bothell, United States.
Cocrystal Pharma, Inc. operates in Pharmaceutical. Its work centres on antiviral therapeutics, clinical-stage biotechnology, COVID-19 therapeutics and influenza viruses. Its customers include Healthcare Providers, Pharmaceutical Companies and Biotechnology Researchers.
Cocrystal Pharma, Inc. has a B2B business model. Its revenue comes from Licensing and Performance Based.
Cocrystal Pharma, Inc. has approximately 16 employees.
Cocrystal Pharma, Inc. has completed 9 funding rounds, raising a total of $89.88M. The latest funding stage is IPO.
Cocrystal Pharma, Inc. offers: Drug Development, Antiviral Research, Clinical Trials, Nobel Prize-winning Expertise.
Top alternatives and competitors to Cocrystal Pharma, Inc. include Atriva Therapeutics GmbH, Tvardi Therapeutics, Redx Pharma, Chemomab Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cocrystal Pharma, Inc. and Atriva Therapeutics GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cocrystal Pharma, Inc., https://bouncewatch.com/company/cocrystal-pharma-inc, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout